Using Molecular Targets to Predict and Treat Aortic Aneurysms

TL;DR

This review explores how molecular targets can improve the prediction and treatment of aortic aneurysms, offering better risk assessment and early diagnosis.

Contribution

The paper highlights novel molecular targets for early diagnosis and targeted treatment of aortic aneurysms.

Findings

Current aneurysm prediction methods based on diameter are insufficient.

Molecular targets offer more accurate risk assessment and early diagnosis.

Some molecular targets are in preclinical stages for therapeutic use.

Abstract

Aortic aneurysms are life-threatening vascular diseases associated with high
morbidity, and usually require prophylactic surgical intervention. Current
preventative management of aortic aneurysms relies on the diameter and other
anatomic parameters of the aorta, but these have been demonstrated to be
insufficient predictive factors of disease progression and potential
complications. Studies on pathophysiology of aortic aneurysms could fill this need, which already indicated the significance
of specific molecules in aortic aneurysms. These molecules provide more accurate
prediction, and they also serve as therapeutic targets, some of which are in
preclinical stage. In this review, we summarized the inadequacies and
achievements of current clinical prediction standards, discussed the molecular
targets in prediction and treatment, and especially emphasized the molecules that
have shown potentials in early diagnosis, accurate risk assessment and target
treatment of aortic aneurysm at early stage.

Figures